EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis

Wanqing Iris Zhi iD, Nechama Dreyfus, Alexie Lessing, Marylou Galantino, Lauren Piulson, Kevin Liu Kot, Susan Li, Ting Bao iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad062 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2023. Verfasst von Wanqing Iris Zhi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Peripheral Nervous System Diseases, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) can lead to chemotherapy dose reduction, delay, and discontinuation, and has limited effective prevention strategies. Our study aimed to identify patient characteristics associated with CIPN severity during weekly paclitaxel chemotherapy in people with early-stage breast cancer.

Methods

We retrospectively collected baseline data including participants’ age, gender, race, body mass index (BMI), hemoglobin (regular and A1C), thyroid stimulating hormone, Vitamins (B6, B12, and D), anxiety, and depression up to 4 months prior to their first paclitaxel treatment. We also collected CIPN severity by Common Terminology Criteria for Adverse Events (CTCAE) after chemotherapy, chemotherapy relative dose density (RDI), disease recurrence, and mortality rate at the time of the analysis. Logistic regression was used for statistical analysis.

Results

We extracted 105 participants’ baseline characteristics from electronic medical records. Baseline BMI was associated with CIPN severity (Odds Ratio [OR] 1.08; 95% CI, 1.01-1.16, P = .024). No significant correlations were observed in other covariates. At median follow-up (61 months), there were 12 (9.5%) breast cancer recurrences and six (5.7%) breast cancer-related deaths. Higher chemotherapy RDI was associated with improved disease-free survival (DFS, OR 1.025; 95% CI, 1.00-1.05; P = .028). Conclusions and Relevance Baseline BMI may be a risk factor for CIPN and suboptimal chemotherapy delivery due to CIPN may negatively impact disease-free survival in patients with breast cancer. Further study is warranted to identify mitigating lifestyle factors to reduce incidences of CIPN during breast cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPeripheral Nervous System DiseasesAntineoplastic AgentsHumansFemaleRetrospective StudiesNeoplasm Recurrence, LocalPaclitaxel

Stichwörter der Autor:innen

body mass indexbreast cancerpaclitaxelperipheral neuropathy

Substanzen

PaclitaxelAntineoplastic Agents

Autor:innen und Institutionen

  • Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Weill Department of Medicine Cornell Medicine, New York, NY, USA.
  • Department of Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.
  • Department of Medicine, School of Health Sciences, Stockton University, Galloway, NJ, USA.
  • Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, NY, USA.

ORCID-Profile: Wanqing Iris Zhi, Ting Bao

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute
  • Memorial Sloan-Kettering Cancer Center

Zitieren

APA

Zhi, W. I., Dreyfus, N., Lessing, A., Galantino, M., Piulson, L., Kot, K. L., Li, S., & Bao, T. (2023). Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyad062

Vancouver

Zhi WI, Dreyfus N, Lessing A, Galantino M, Piulson L, Kot KL, et al. Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis. The Oncologist. 2023. doi:10.1093/oncolo/oyad062

BibTeX
@article{Zhi2023,
  author = {Zhi, Wanqing Iris and Dreyfus, Nechama and Lessing, Alexie and Galantino, Marylou and Piulson, Lauren and Kot, Kevin Liu and Li, Susan and Bao, Ting},
  title = {Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad062}
}
Kostenlos starten →